No Detail Found!

Association of serum advanced glycation (AGEs) end products, apolipoprotein-B and zinc in severity of T2DM retinopathy

Author(s)
Nazish Butt Department of Biochemistry, University of Health Sciences,Lahore,Pakistan
Farhat Bano Department of Biochemistry, University of Health Sciences,Lahore,Pakistan
Mansoor Ghani Department of Biochemistry, University of Health Sciences,Lahore,Pakistan
Atif Mansoor Ahmed Ophthalmology, Sheikh Zayed Hospital and Postgraduate Medical Institute,Lahore,Pakistan
Nauman Majeed Department of Chemical Pathology, Indus Hospital,Karachi,Pakistan
Abstract
Advanced glycation end products (AGEs), lipids and lipoproteins and antioxidant enzymes are involved in the development of diabetic retinopathy (DR). AGEs and modified Apolipoprotein-B (Apo-B) lead to the formation of reactive oxygen species causing damage to the retina leading to DR. Zinc has antioxidant properties and protects the retina against reactive oxygen species. The current study aimed to compare the levels of serum AGEs, Apo-B and zinc in non-diabetics and type II diabetics without and with DR. Serum AGEs and Apo-B were measured by ELISA while zinc was measured by atomic absorption spectrophotometry. The impact of all three markers on the severity of DR was calculated, individually as well as together as a model, to determine the relationship of these markers with severity of diabetic retinopathy. Regression analysis showed that AGEs, Apo-B and zinc were all contributing significantly to the severity of DR, together having an 82.8% impact on it (R2=0.828). The model of the three parameters was best fit to indicate the severity of DR (p-value = 0.553). This study provides a basis for further validation of the suggested model with prospective studies which can then be used in clinical setups to predict the individuals at risk.
Publication Details
Page(s) 803-808
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: SUP2, Year: 2021

Request the full text from PASTIC

Keywords
Advanced glycation end products, Diabetic Retinopathy, proliferative diabetic retinopathy, Non-Proliferative Diabetic Retinopathy, Zinc, apolipoprotein-B
References
Ahsan H .2015 .Diabetic retinopathy -Biomolecules and multiple pathophysiology. Diabetes Metab. Syndr, 9(1) : 51-54.
Chan DT,Dogra GK,Irish AB,Ooi EM,Barrett PH,Chan DC,Watts GF .2009 .Chronic kidney disease delays VLDL-apoB-100 particle catabolism: Potential role of apolipoprotein C-III. J. Lipid Res., 50(12) : 2524-2531.
Chasapis CT,Ntoupa PSA,Spiliopoulou CA,Stefanidou ME .2020 .Recent aspects of the effects of zinc on human health. Arch. Toxicl., 94(5) : 1443-1460.
Deguchi Y,Maeno T,Saishin Y,Hori Y,Shiba T,Takahashi M .2011 .Relevance of the serum apolipoprotein ratio to diabetic retinopathy. Jpn. J. Ophthalmol., 55(2) : 128-131.
Duh EJ,Sun JK,Stitt AW .2017 .Diabetic retinopathy: current understanding, mechanisms and treatment strategies. JCI Insight, 2(14) : e93751.
Frondelius K,Borg M,Ericson U,Borne Y,Melander O,Sonestedt E .2017 .Lifestyle and dietary determinants of serum apolipoprotein a1 and apolipoprotein b concentrations: Cross-sectional analyses within a Swedish cohort of 24,984 individuals. , 9(3) : 211.
Page S Hewapathirana N .2012 .Diabetic microvascular complications - screening, diagnosis and prevention. Clin. Focus Pri. Care, 6(3) : 177-191.
Hu A,Luo Y,Li T,Guo X,Ding X,Zhu X,Wang X,Tang S X .2012 .Low serum apolipoprotein A1/B ratio is associated with proliferative diabetic retinopathy in type 2 diabetes. Graefes Arch. Clin. Exp, 250(7) : 957-962.
Jarosz M,Olbert M,Wuszogrodzka G,Mlyniec K,Librowski T .2017 .Antioxidant and antiinflammatory effects of zinc. Zinc-dependent NF-κB signaling. Inflammopharmacology, 25(1) : 11-24.
Kanani FH,Alam JM .2010 .Apolipoprotein B in Type 2 diabetics a cross sectional study in a tertiary care set-up. JPMA, 60(8) : 653.
Khalid N,Ahmed DA,Bhatti M,Randhawa M,Ahmad A,Rafaqat R .2014 .A question mark on zinc deficiency in 185 million people in Pakistan-possible way out. Crit. Rev. Food Sci. Nutr, 54(9) : 1222-40.
Kilhovd BK,Berg TJ,Birkeland KI,Thorsby P,Hanssen KF .1999 .Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care, 22(9) : 1543-1548.
Pak. J. Pharm. Sci. ,Koska J,Saremi A,Howell S,Bahn G,De Courten B,Ginsberg H,Beisswenger PJ,Reaven PD .2018 .Advanced glycation end products, Oxidation products, and incident cardiovascular events in patients with type 2 diabetes. Diabetes Care, 41(3) : 570-576.
Kumari S,Pradhan T,Panda T,Bangladesh J. M. Sci T .2014 .Trace Minerals and Oxidative Stress in Diabetic Retinopathy. , 13(2) : 175-179.
Luo YY,Zhao J,Han XY,Zhou XH,Wu J,Ji LN .2015 .Relationship between serum zinc level and microvascular complications in patients with type 2 diabetes. , 128(24) : 3276.
Movahedi Rad M,Rabizadeh S,Salehi S,Mirmiranpour H,Esteghamati A,Jafari R,Nakhjavani M .2017 .Advanced end glycation products, Advanced oxidation protein products and ferritin reducing ability of plasma as markers of diabetic retinopathy. Austin J. Endo. Diabetes, 4(1) : 1057-1062.
Namitha D,Nusrath A,Rajeswari A,Rani NA,Shilpashree YD .2017 .Apolipoprotein A-1 and apolipoprotein B: Better indicators of dyslipidemia in diabetic retinopathy patients? Indian J. , 21(2) : 142-146.
Ono Y,Aoki S,Ohnishi K,Yasuda T,Kawano K,Tsukada Y .1998 .Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res. Clin. Pract, 41(2) : 131-137.
Prakash G,Agrawal R,Satsangi SK,Prakash S SK .2016 .Comparison of Serum Apolipoproteins and Traditional Lipids in Eyes with Diabetic Retinopathy in Indian Population: A Case Series. Middle East Afr. , 23(2) : 212-214.
Prasad AS .2014 .Zinc is an antioxidant and antiinflammatory agent: Its role in human health. Frontiers in Nutrition, 1(14) : 1-10.
Praveena S,Sujatha P,Ganesh B .2013 .Study of micro elements in Diabetic Retinopathy. J. Med, 2(6) : 531-537.
Rathnakumar Krishnamoorthy RK,Ramesh Venkatachalam R Poovitha and Geetha Rajagopalan RK .2017 .Apolipoproteins an early and better diagnostic marker for diabetic retinopathy. J. Clin. Diagnostic Res., 11(10) : NC01-NC05.
Sasongko MB,Wong TY,Nguyen TT,Kawasaki R,Jenkins A,Shaw J,Wang JJ .2011 .Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care, 34(2) : 474-479.
Sharma Y,Saxena S,Mishra A,Saxena A,Natu SM .2012 .Advanced glycation end products and diabetic retinopathy. J. Ocul. Bio, 5(3) : 63-69.
Wagner Z,Wittmann I,Mazak I,Schinzel R,Heidland A,Kienysch-Engel R,Nagy J .2001 .Nϵ- (carboxymethyl) lysine levels in patients with type 2 diabetes: Role of renal function. AJKDD, 38(4) : 785-791.
Wilkinson CP,Ferris FL,Klein RE,Lee PP,Agardh CD,Davis M,Dills D,Kampik A,Pararajasegaram R,Verdaguer JT .2003 .Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology, 110(9) : 1677-1682.
Wu M,Chen Y,Wilson K,Chirindel A,Ihnat MA,Yu Y,Boulton ME,Szweda LI,Ma JX,Lyons TJ .2008 .Intraretinal leakage and oxidation of LDL in diabetic retinopathy. IOVS, 49(6) : 2679-85.
Yu JY,Lyons TJ .2013 .Modified lipoproteins in diabetic retinopathy: A local action in the retina. J. Clin. Exp, 4(6) : 314.
0

Citations

0

Downloads

10

Views